CVS Health Corporation (CVS)
| Previous close | 73.50 |
| Open | 73.97 |
| Bid | 74.49 x 800 |
| Ask | 74.50 x 1300 |
| Day's range | 73.48 - 74.72 |
| 52-week range | 64.41 - 104.83 |
| Volume | |
| Avg. volume | 7,575,538 |
| Market cap | 96.119B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 11.44 |
| EPS (TTM) | 6.53 |
| Earnings date | 06 Feb 2024 - 12 Feb 2024 |
| Forward dividend & yield | 2.66 (3.62%) |
| Ex-dividend date | 19 Jan 2024 |
| 1y target est | 80.77 |
Motley FoolWhy CVS Health Stock Rallied Wednesday Morning
Shares of CVS Health (NYSE: CVS) rallied out of the gate on Wednesday morning, adding as much as 4.7%. The catalyst that sent the healthcare giant higher was bullish takes from a trio of Wall Street analysts. In the wake of the company's investor day on Tuesday, analysts are more bullish on the future prospects and the growing opportunity for CVS.
CNN BusinessCVS is shaking up drug pricing. You can thank Mark Cuban
The way pharmacies in the United States make money is … kind of a mystery.
Motley FoolWhy CVS Health Jumped Nearly 4% Today
Shares of drugstore chain CVS Health (NYSE: CVS) are higher by nearly 4% as of 3:24 p.m. ET Tuesday following an important update from the company. While the bulk of today's press release lays out plans to overhaul its prescription drug-pricing paradigm and improve its primary care operation, investors are most likely responding to the company's bullish guidance for fiscal/calendar 2024. In the coming year, the company's pharmacy customers will see more detailed information regarding their prescription-drugs' costs as well as their insurer's portion of the total cost; in some cases, customers may see lower prescription-drug prices.
